Multifunctional Envelope-Type siRNA Delivery Nanoparticle Platform for Prostate Cancer Therapy

Area of Science:

• Biotechnology
• Nanomedicine
• Oncology

Background:

• RNA interference (RNAi) offers therapeutic potential but faces delivery challenges.
• Effective delivery of small interfering RNA (siRNA) to non-liver tissues, like tumors, is crucial for RNAi therapy.
• Prostate cancer (PCa) requires targeted therapeutic strategies for effective treatment.

Purpose of the Study:

• To develop a multifunctional nanoparticle (NP) platform for prostate cancer-specific in vivo siRNA delivery.
• To create a nanoplatform capable of targeting prostate-specific membrane antigen (PSMA)-expressing PCa cells.
• To evaluate the therapeutic efficacy of the developed nanoplatform in inhibiting PCa tumor growth.

Main Methods:

• Synthesized oligoarginine-functionalized, pH-responsive polymers for self-assembly with siRNA into NPs.
• Modified NPs with ACUPA, a ligand targeting the PSMA receptor, for PCa cell specificity.
• Administered siRNA NPs systemically to evaluate gene silencing and tumor inhibition in vivo.

Main Results:

• The developed NPs exhibited long blood circulation and pH-triggered endosomal escape via oligoarginine mediation.
• ACUPA modification enabled efficient targeting of PSMA-expressing PCa cells.
• Systemic delivery of siRNA NPs effectively silenced prohibitin 1 (PHB1) and significantly inhibited PCa tumor growth.

Conclusions:

• The multifunctional envelope-type nanoplatform demonstrates efficient and specific delivery of siRNA for PCa therapy.
• This nanoplatform holds promise as an effective tool for targeting PSMA-expressing prostate cancer.
• The study highlights the potential of advanced nanomedicine in cancer treatment.